Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Pregnancy in beta-thalassemia intermedia: 20-year experience of a Greek thalassemia center.

Voskaridou E, Balassopoulou A, Boutou E, Komninaka V, Christoulas D, Dimopoulou M, Delaki EE, Loukopoulos D, Terpos E.

Eur J Haematol. 2014 Dec;93(6):492-9. doi: 10.1111/ejh.12387. Epub 2014 Jun 26.

PMID:
24889414
2.

Haemoglobinopathies in Greece: prevention programme over the past 35 years.

Loukopoulos D.

Indian J Med Res. 2011 Oct;134:572-6. Review.

3.

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Blood. 2010 Mar 25;115(12):2354-63. doi: 10.1182/blood-2009-05-221333. Epub 2009 Nov 10.

PMID:
19903897
4.

No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients.

Politou M, Zoi C, Dahabreh IJ, Rallidis L, Gialeraki A, Loukopoulos D, Zoi K.

Leukemia. 2009 May;23(5):1008-9. doi: 10.1038/leu.2008.368. Epub 2009 Jan 8. No abstract available.

PMID:
19151782
5.

No evidence for increased prevalence of JAK2 V617F in women with a history of recurrent miscarriage.

Dahabreh IJ, Jones AV, Voulgarelis M, Giannouli S, Zoi C, Alafakis-Tzannatos C, Varla-Leftherioti M, Moutsopoulos HM, Loukopoulos D, Fotiou S, Cross NC, Zoi K.

Br J Haematol. 2009 Mar;144(5):802-3. doi: 10.1111/j.1365-2141.2008.07510.x. Epub 2008 Nov 17. No abstract available.

PMID:
19036091
6.

Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.

Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M.

Leuk Res. 2009 Jan;33(1):67-73. doi: 10.1016/j.leukres.2008.06.006. Epub 2008 Jul 15.

PMID:
18632151
7.

Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.

Kouroupi E, Zoi K, Parquet N, Zoi C, Kiladjian JJ, Grigoraki V, Vainchenker W, Lellouche F, Marzac C, Schlageter MH, Dosquet C, Scott LM, Fenaux P, Loukopoulos D, Chomienne C, Cassinat B.

Br J Haematol. 2008 Aug;142(4):676-9. doi: 10.1111/j.1365-2141.2008.07223.x. Epub 2008 May 22. No abstract available.

PMID:
18503583
8.

Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity.

Zoi K, Terpos E, Zoi C, Loukopoulos D.

Br J Haematol. 2008 Apr;141(1):100-4. doi: 10.1111/j.1365-2141.2008.06993.x.

PMID:
18324972
9.

Hypereosinophilic syndrome: another face of janus?

Dahabreh IJ, Giannouli S, Zoi C, Zoi K, Loukopoulos D, Voulgarelis M.

Leuk Res. 2008 Sep;32(9):1483-5. doi: 10.1016/j.leukres.2007.12.007. Epub 2008 Feb 19. No abstract available.

PMID:
18243306
10.

Factors mediating lipofection potency of a series of cationic phosphonolipids in human cell lines.

Koumbi D, Clement JC, Sideratou Z, Yaouanc JJ, Loukopoulos D, Kollia P.

Biochim Biophys Acta. 2006 Aug;1760(8):1151-9. Epub 2006 Apr 19.

PMID:
16730412
11.

Early markers of renal dysfunction in patients with sickle cell/beta-thalassemia.

Voskaridou E, Terpos E, Michail S, Hantzi E, Anagnostopoulos A, Margeli A, Simirloglou D, Loukopoulos D, Papassotiriou I.

Kidney Int. 2006 Jun;69(11):2037-42.

12.

Combined therapy with deferiprone and desferrioxamine in thalassemia major.

Loukopoulos D.

Haematologica. 2005 Oct;90(10):1304-5. No abstract available.

13.

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders.

Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC.

Blood. 2005 Sep 15;106(6):2162-8. Epub 2005 May 26.

PMID:
15920007
14.

Deferiprone as an oral iron chelator in sickle cell disease.

Voskaridou E, Douskou M, Terpos E, Stamoulakatou A, Meletis J, Ourailidis A, Papassotiriou I, Loukopoulos D.

Ann Hematol. 2005 Jul;84(7):434-40. Epub 2005 Apr 5.

PMID:
15809885
15.

HbO-Arab mutation originated in the Pomak population of Greek Thrace.

Papadopoulos V, Dermitzakis E, Konstantinidou D, Petridis D, Xanthopoulidis G, Loukopoulos D.

Haematologica. 2005 Feb;90(2):255-7.

16.

Red cell macrocytosis in hypoxemic patients with chronic obstructive pulmonary disease.

Tsantes AE, Papadhimitriou SI, Tassiopoulos ST, Bonovas S, Paterakis G, Meletis I, Loukopoulos D.

Respir Med. 2004 Nov;98(11):1117-23.

17.

Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.

Voskaridou E, Douskou M, Terpos E, Papassotiriou I, Stamoulakatou A, Ourailidis A, Loutradi A, Loukopoulos D.

Br J Haematol. 2004 Sep;126(5):736-42.

PMID:
15327528
18.

Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.

Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D.

Br J Haematol. 2003 Nov;123(4):730-7.

PMID:
14616979
19.

Theophylline treatment may adversely affect the anoxia-induced erythropoietic response without suppressing erythropoietin production.

Tsantes AE, Tassiopoulos ST, Papadhimitriou SI, Bonovas S, Poulakis N, Vlachou A, Filioussi K, Loukopoulos D.

Eur J Clin Pharmacol. 2003 Sep;59(5-6):379-83. Epub 2003 Aug 5.

PMID:
12904930
20.

Analysis of the A(TA)(n)TAA configuration in the promoter region of the UGT1 A1 gene in Greek patients with thalassemia intermedia and sickle cell disease.

Kalotychou V, Antonatou K, Tzanetea R, Terpos E, Loukopoulos D, Rombos Y.

Blood Cells Mol Dis. 2003 Jul-Aug;31(1):38-42.

PMID:
12850481
21.

Clonal analysis of granulocyte-monocyte colony-forming unit cells with the human androgen receptor gene in chronic myeloid leukemia.

Akel S, Mavroyanni D, Yataganas X, Terpos E, Meletis J, Anargyrou K, Stavrogianni N, Pangalis GA, Loukopoulos D, Viniou N.

Int J Hematol. 2003 Jun;77(5):476-81.

PMID:
12841386
22.

Ethical issues: should we give the predictive genetic profile to the citizens?

Dembinska-Kiec A, Madan T, Batt AM, Vincent-Viry M, Schmitz G, Van Helden PD, Poulis P, Walter JE, Naskalski J, Loukopoulos D, Baranova H.

Clin Chem Lab Med. 2003 Apr;41(4):559-63. No abstract available.

PMID:
12747603
23.

Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.

Steinberg MH, Voskaridou E, Kutlar A, Loukopoulos D, Koshy M, Ballas SK, Castro O, Barton F.

Am J Hematol. 2003 Feb;72(2):121-6.

24.

Arthropathy in juvenile hemochromatosis.

Vaiopoulos G, Papanikolaou G, Politou M, Jibreel I, Sakellaropoulos N, Loukopoulos D.

Arthritis Rheum. 2003 Jan;48(1):227-30.

25.

Genetic heterogeneity underlies juvenile hemochromatosis phenotype: analysis of three families of northern Greek origin.

Papanikolaou G, Papaioannou M, Politou M, Vavatsi N, Kioumi A, Tsiatsiou P, Marinaki P, Loukopoulos D, Christakis JI.

Blood Cells Mol Dis. 2002 Sep-Oct;29(2):168-73.

PMID:
12490283
26.

Elastic tissue abnormalities in inherited haemolytic syndromes.

Aessopos A, Farmakis D, Loukopoulos D.

Eur J Clin Invest. 2002 Sep;32(9):640-2. No abstract available.

PMID:
12486861
27.

Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B.

Gogas H, Paterakis G, Frangia K, Bafaloukos D, Pectasides D, Kalofonos HP, Loukopoulos D, Stavropoulou-Giokas C, Ioannovich J, Mihm MC Jr.

Am J Clin Oncol. 2002 Dec;25(6):591-6.

PMID:
12478006
28.

Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Roetto A, Papanikolaou G, Politou M, Alberti F, Girelli D, Christakis J, Loukopoulos D, Camaschella C.

Nat Genet. 2003 Jan;33(1):21-2. Epub 2002 Dec 9.

PMID:
12469120
29.

Efficiency of interphase fluorescence in situ hybridization for BCR/ABL on peripheral blood smears for monitoring of CML patients: a comparison with bone marrow findings.

Akel S, Kolialexi A, Mavrou A, Metaxotou C, Loukopoulos D, Yataganas X.

Clin Lab Haematol. 2002 Dec;24(6):361-7.

PMID:
12452817
30.

Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.

Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, Tsoutsos D, Panagiotou P, Ioannovich J, Loukopoulos D.

Br J Cancer. 2002 Jul 15;87(2):181-6.

31.

Danazol therapy for thrombocytopenia in patients with myelodysplastic syndromes.

Viniou N, Plata E, Terpos E, Variami E, Meletis J, Vaiopoulos G, Loukopoulos D, Chatzidimitriou G, Yataganas X.

Acta Haematol. 2002;107(4):234-6. No abstract available.

PMID:
12053153
32.

Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.

Mavrogianni D, Viniou N, Michali E, Terpos E, Meletis J, Vaiopoulos G, Madzourani M, Pangalis G, Yataganas X, Loukopoulos D.

Int J Hematol. 2002 May;75(4):394-400.

PMID:
12041671
33.

Functional role of the four different types of (AT)(x)T(y) motifs 5' to the beta-globin gene and their distribution in the Greek population.

Kalotychou V, Kollia P, Voskaridou E, Patargias T, Anagnou NP, Loukopoulos D.

Blood Cells Mol Dis. 2002 Jan-Feb;28(1):39-46.

PMID:
11987240
34.

Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.

Viniou N, Terpos E, Galanopoulos A, Kritikou-Griva E, Akel S, Michalis E, Apostolidou E, Georgiadou D, Kouraklis A, Parharidou A, Kokkini G, Symeonidis A, Anagnostopoulos NI, Christakis JI, Tasiopoulou A, Loukopoulos D, Yataganas X.

Ann Hematol. 2002 Apr;81(4):182-6. Epub 2002 Mar 27.

PMID:
11976818
35.

Acute Aspergillosis gastritis in a case of fatal aplastic anemia.

Konstantopoulos K, Agapitos E, Komninaka V, Kritsova V, Meletis J, Delaveris E, Loukopoulos D.

Scand J Infect Dis. 2002;34(2):148-9.

PMID:
11928854
36.

Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.

Meletis J, Terpos E, Samarkos M, Meletis C, Apostolidou E, Komninaka V, Korovesis K, Mavrogianni D, Boutsis D, Variami E, Viniou N, Konstantopoulos K, Loukopoulos D.

Hematol J. 2001;2(1):33-7.

PMID:
11920231
37.

Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.

Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D.

Hematol J. 2000;1(5):295-300.

PMID:
11920206
38.

Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.

Voskaridou E, Terpos E, Komninaka V, Eftyhiadis E, Mantzourani M, Loukopoulos D.

Br J Haematol. 2002 Jan;116(1):155-7.

PMID:
11841409
39.

Linkage to chromosome 1q in Greek families with juvenile hemochromatosis.

Papanikolaou G, Politou M, Roetto A, Bosio S, Sakelaropoulos N, Camaschella C, Loukopoulos D.

Blood Cells Mol Dis. 2001 Jul-Aug;27(4):744-9.

PMID:
11778658
40.

Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes.

Aessopos A, Farmakis D, Loukopoulos D.

Blood. 2002 Jan 1;99(1):30-5. Review.

PMID:
11756149
41.

Familial Mediterranean fever phenotype II in Greece.

Konstantopoulos K, Kanta A, Tzoulianos M, Dimou S, Sotsiou F, Politou M, Loukopoulos D.

Isr Med Assoc J. 2001 Nov;3(11):862-3. No abstract available.

42.

Molecular analysis of transferrin receptor mRNA expression in acute myeloid leukaemia.

Kollia P, Stavroyianni N, Stamatopoulos K, Zoi K, Viniou N, Mantzourani M, Noguchi CT, Paterakis G, Abazis D, Pangalos C, Loukopoulos D, Yataganas X.

Br J Haematol. 2001 Oct;115(1):19-24.

PMID:
11722405
43.

Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia.

Atweh GF, Loukopoulos D.

Semin Hematol. 2001 Oct;38(4):367-73. Review.

PMID:
11605172
44.

Exercise-induced myocardial perfusion abnormalities in sickle beta-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study.

Aessopos A, Tsironi M, Vassiliadis I, Farmakis D, Fountos A, Voskaridou E, Perakis A, Defteraios S, Loutradi A, Loukopoulos D.

Am J Med. 2001 Oct 1;111(5):355-60.

PMID:
11583637
45.

Valproic acid, trichostatin and their combination with hemin preferentially enhance gamma-globin gene expression in human erythroid liquid cultures.

Marianna P, Kollia P, Akel S, Papassotiriou Y, Stamoulakatou A, Loukopoulos D.

Haematologica. 2001 Jul;86(7):700-5.

46.

Clinical significance of the molecular detection of melanoma cells circulating in the peripheral blood in melanoma patients.

Konstantopoulos K, Psatha M, Kalotychou V, Frangia N, Ioannovits I, Meletis I, Loukopoulos D.

Panminerva Med. 2001 Jun;43(2):109-13.

PMID:
11449181
47.

Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature.

Vaiopoulos G, Terpos E, Viniou N, Nodaros K, Rombos J, Loukopoulos D.

Am J Hematol. 2001 Jan;66(1):57-8.

48.

Agamma-haplotypes: a new group of genetic markers for thalassemic mutations inside the 5' regulatory region of the human Agamma-globin gene.

Patrinos GP, Kollia P, Papapanagiotou E, Loutradi-Anagnostou A, Loukopoulos D, Papadakis MN.

Am J Hematol. 2001 Feb;66(2):99-104.

49.

Erythropoiesis: Hereditary Spherocytosis in Greece: Collective Data on a Large Number of Patients.

Premetis E, Stamoulakatou A, Loukopoulos D.

Hematology. 1999;4(4):361-366.

PMID:
11399577
50.

Malignancy: Molecular Demonstration of BCR/ABL Fusion in a Patient with Chronic Myelogenous Leukemia with Basophilia Carrying a Variant t(16;22) (q24;q11) Philadelphia Chromosome.

Mantzourani M, Stavroyianni N, Abazis D, Kyriazopoulos P, Pangalos C, Loukopoulos D, Yataganas X.

Hematology. 1999;4(3):211-216.

PMID:
11399565

Supplemental Content

Loading ...
Support Center